Report on extraordinary general meeting held in NeuroSearch A/S

Not for release, publication or distribution in Australia, Canada, Japan
or the United States.                                                         


Announcement


Report on extraordinary general meeting held in NeuroSearch A/S

Pursuant to announcement, the extraordinary general meeting of NeuroSearch A/S
was held today Friday 23 May 2008.                                            

The suggested amendments to the Articles of Association were adopted by the     
general meeting: article 5 following which the board of directors is authorised 
to increase the company's capital in one or more issues of a total nominal value
of DKK 80,000,000 (4.000.000 shares of DKK 20 each) until 30 December 2012 and  
article 5a following which the board of directors is authorised to issue        
warrants by one or more issues for up to a total nominal value of DKK 7,000,000 
shares to some or all of the company's or the company's subsidiaries' employees,
board members and management on terms laid down by the board of directors for   
the period ending on 31 December 2009.                                          


Thomas Hofman-Bang  
Chairman of the board


Contact persons:
Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4017 5103                     



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of     
novel drugs, based on a broad and well-established drug discovery platform      
focusing on ion channels and CNS disorders. A substantial part of the company's 
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase  
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in     
partnership with GSK, NS1209 in epilepsy/pain (Phase II), ABT-894 in ADHD (Phase
II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia      
(Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's  
disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS  
diseases - both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o.    
(Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I).  
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates   
and holds equity interests in several biotech companies.